Profile data is unavailable for this security.
About the company
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.
- Revenue in USD (TTM)1.88m
- Net income in USD-15.57m
- Incorporated2014
- Employees35.00
- LocationBeyondspring Inc100 Campus DriveWest Side, 4Th Floor, Suite 410FLORHAM PARK 07932United StatesUSA
- Phone+1 (646) 528-4184
- Websitehttps://www.beyondspringpharma.com/en/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medicinova Inc | 1.00m | -8.16m | 82.89m | 13.00 | -- | 1.44 | -- | 82.89 | -0.1665 | -0.1665 | 0.0204 | 1.17 | 0.0155 | -- | -- | 76,923.08 | -12.65 | -15.36 | -13.19 | -15.90 | -- | -- | -816.49 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
| Ovid Therapeutics Inc | 567.53k | -29.75m | 83.04m | 40.00 | -- | 0.934 | -- | 146.31 | -0.4218 | -0.4218 | 0.008 | 1.25 | 0.0045 | -- | -- | 14,188.25 | -23.39 | -20.78 | -25.86 | -23.27 | -- | -- | -5,241.56 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| Bioatla Inc | 0.00 | -104.56m | 84.10m | 65.00 | -- | 2.68 | -- | -- | -2.18 | -2.18 | 0.00 | 0.6491 | 0.00 | -- | -- | 0.00 | -84.23 | -48.72 | -106.06 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| Aclaris Therapeutics Inc | 32.02m | -58.68m | 86.33m | 91.00 | -- | 0.645 | -- | 2.70 | -0.8267 | -0.8267 | 0.4509 | 1.88 | 0.1614 | -- | 84.70 | 351,824.20 | -29.58 | -47.29 | -32.76 | -53.87 | 42.63 | 44.00 | -183.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Benitec Biopharma Inc | 7.00k | -21.69m | 86.99m | 18.00 | -- | 2.04 | -- | 12,427.54 | -9.87 | -9.87 | 0.0031 | 4.22 | 0.0006 | -- | 0.1284 | 388.89 | -186.85 | -83.43 | -260.89 | -98.77 | 1,542.86 | 96.86 | -309,885.70 | -468.04 | -- | -307.03 | 0.00 | -- | 2.74 | -53.84 | -7.44 | -- | -56.51 | -- |
| Beyondspring Inc | 1.88m | -15.57m | 89.06m | 35.00 | -- | -- | -- | 47.48 | -0.3987 | -0.3987 | 0.0481 | -0.749 | 0.0698 | -- | -- | 52,111.11 | -59.75 | -75.50 | -102.15 | -96.48 | -- | -- | -856.29 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
| Hillevax Inc | 0.00 | -156.27m | 90.11m | 90.00 | -- | 0.4353 | -- | -- | -3.38 | -3.38 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -55.47 | -- | -63.02 | -- | -- | -- | -- | -- | -- | -- | 0.1113 | -- | -- | -- | 22.68 | -- | -- | -- |
| Allovir Inc | 0.00 | -140.34m | 91.14m | 112.00 | -- | 0.7573 | -- | -- | -1.23 | -1.23 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -67.85 | -52.85 | -73.72 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
| CytomX Therapeutics Inc | 119.57m | 11.09m | 91.40m | 120.00 | 8.53 | -- | 7.04 | 0.7644 | 0.1371 | 0.1371 | 1.45 | -0.3997 | 0.6491 | -- | 51.12 | 996,408.30 | 6.02 | -21.53 | 26.34 | -32.32 | -- | -- | 9.27 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
| Karyopharm Therapeutics Inc | 145.67m | -89.91m | 92.15m | 325.00 | -- | -- | -- | 0.6326 | -0.8356 | -0.8356 | 1.17 | -1.06 | 0.5692 | 1.62 | 4.15 | 448,209.20 | -35.14 | -53.02 | -45.50 | -65.85 | 96.04 | 97.18 | -61.72 | -125.15 | 3.56 | -7.37 | 2.00 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| Ikena Oncology Inc | 1.84m | -66.71m | 93.41m | 18.00 | -- | 0.5776 | -- | 50.66 | -1.43 | -1.43 | 0.0393 | 2.96 | 0.0112 | -- | -- | 42,883.72 | -40.52 | -29.72 | -43.17 | -34.62 | -- | -- | -3,617.57 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| Coya Therapeutics Inc | 9.55m | -10.10m | 94.68m | 8.00 | -- | 2.69 | -- | 9.91 | -0.7726 | -0.7726 | 0.7589 | 2.32 | 0.3512 | -- | -- | 1,194,290.00 | -37.13 | -- | -40.92 | -- | -- | -- | -105.71 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Boundless Bio Inc | 0.00 | -57.72m | 95.03m | 72.00 | -- | 0.5302 | -- | -- | -2.60 | -2.60 | 0.00 | 8.05 | 0.00 | -- | -- | 0.00 | -33.64 | -- | -35.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| bluebird bio Inc | 45.69m | -302.96m | 95.41m | 375.00 | -- | 0.7268 | -- | 2.09 | -2.44 | -2.44 | 0.3452 | 0.677 | 0.069 | 3.28 | -- | 121,837.30 | -45.76 | -34.75 | -66.24 | -40.84 | -22.60 | -124.35 | -663.09 | -5,770.41 | 0.8219 | -28.60 | 0.615 | -- | 720.04 | -11.58 | 8.00 | -- | -30.47 | -- |
Data as of Sep 19 2024. Currency figures normalised to Beyondspring Inc's reporting currency: US Dollar USD
1.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Citigroup Global Markets, Inc. (Investment Management)as of 30 Jun 2024 | 454.25k | 1.13% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 114.51k | 0.28% |
| BlackRock Financial Management, Inc.as of 30 Jun 2024 | 87.44k | 0.22% |
| Tanaka Capital Management, Inc.as of 30 Jun 2024 | 29.47k | 0.07% |
| Geode Capital Management LLCas of 30 Jun 2024 | 24.37k | 0.06% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 16.89k | 0.04% |
| UBS Securities LLCas of 30 Jun 2024 | 16.88k | 0.04% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 14.39k | 0.04% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 12.50k | 0.03% |
| BlackRock Investment Management LLCas of 30 Jun 2024 | 10.05k | 0.03% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
